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When neurons go astray
Recent prospective studies indicate that schizophrenia manifests itself
in behavioural abnormalities much earlier than was previously thought,
supporting the view that schizophrenia is a developmental disorder.
Schizophrenia is a syndrome characterized by delusions,
hallucinations, thought disorders and impaired social
relationships. Patients come to the attention of doctors
between the ages of 18 and 30. The outcome of the dis-
ease is variable, but as many as 60 % of patients will have
difficulties coping with the disease for the rest of their
life. The extent of these difficulties will vary and is almost
impossible to predict at the onset of the disease. Many
patients receive considerable help from treatment with
neuroleptic drugs and the provision of appropriate social
support in the community. The population lifetime risk
of schizophrenia is about 1 % - at any one time, some
200000 patients have the disease in the UK, and almost
1 000000 in the USA [1]. The economic costs of the dis-
ease run to almost C2 billion a year in the UK. The
variation in the severity of the disease is such that 97 % of
the costs are incurred by less than 50 % of the patients.
Neuroleptic drugs revolutionized the treatment of
schizophrenia in the 1960s, and newer 'atypical' neu-
roleptics such as clozapine and risperidone have produced
additional significant gains in efficacy. But we are still in a
position in which some 30 % of patients show only lim-
ited improvements when treated with neuroleptics, and
10-20 % show little or no improvement. Clearly, there is
scope for a massive improvement in the efficacy of our
therapeutic armoury. There is, however, a considerable
snag. Improved efficacy is often contingent on a clearer
understanding of the disease process. No advances were
made on this front until recently. The result of this recent
work has been a startling paradigm shift in our view of the
disease process in schizophrenia. There is now a mounting
body of evidence to support the view that schizophrenia is
a consequence of a disorder in development of the brain.
For decades, schizophrenia was considered to be a 'func-
tional' psychosis. A consequence of this was the tacit
assumption that aberrant or degenerate brain structures
played no significant role in the disease process. The
dominance of 'psychogenic' hypotheses of the disease
was only challenged after the introduction of imaging
technologies. Following the seminal computer tomo-
graphic study of Johnstone and colleagues in 1976,
numerous other workers demonstrated the presence of
structural abnormalities in the brains of schizophrenia
patients. Recent magnetic resonance imaging (MRI)
studies have confirmed the presence of a diffuse reduc-
tion in brain volume (primarily of the grey matter),
which is most pronounced in the regions of the medial
temporal lobe [2,3]. Positron emission tomography
(PET) and MRI spectroscopy studies have also revealed
changes in brain metabolism in the frontal and temporal
lobes [4,5], and the changes in structure and metabolism
appear to be related [5]. These studies are supported by a
series of neuropathological investigations, which have
also documented volume loss in the entorhinal cortex,
hippocampus and related structures (see [6] for review).
Morphological investigations of the brains of schizo-
phrenia patients have revealed disordered arrangements
of neurons within the medial temporal lobe (entorhinal
cortex, layer II pre-xt cells), coupled with varying
degrees of volume or neuron loss in the same region [6].
A distorted distribution of NADPH-diaphorase positive
interneurons has also been reported [7]. This latter find-
'ing has been interpreted as indicating a perturbation in
the functioning of the cortical subplate, with consequent
disturbances in neuronal migration and cortical connec-
tivity [7]. Thus, neurons going astray seem to be a central
feature of the pathology of schizophrenia. The entorhinal
cortex/parahippocampal gyrus forms a critical 'nodal
way station' in the circuitry connecting the association
cortex with the hippocampus and subcortical structures
(Fig. 1). The aberrant organization of neurons within the
medial temporal lobe is therefore likely to have major
consequences for higher cortical function.
Although there is general agreement that there are
structural changes in schizophrenia brains, there has
been considerable discussion - diplomatic-speak for
acrimonious rows - about the mechanisms causing such
changes. Candidate aetiological agents have been pro-
posed, largely on the basis of epidemiological data,
including viruses, obstetric complications, birth traumas
and autoimmune disorders. From an epidemiological
standpoint, the debate has been inconclusive. There is,
however, considerable evidence from neuropathological
studies to support the view that the abnormal brain
development in schizophrenia results from a failure of
normal brain development in the fetus. The structural
changes observed do not appear to be associated with
signs of degenerative or inflammatory processes [6].
These neuropathological studies provide the strongest
evidence that the most likely cause of schizophrenia is a
neurodevelopmental lesion, and that traumatic or degen-
erative aetiologies have, at best, a modest role in the
pathogenesis of the disease [6].
This view that schizophrenia is a neurodevelopmental
disease leads to several simple, but profound, predictions.
© Current Biology 1995, Vol 5 No 4342
. . YST  AND G. . ROBERTS CHIZOPHRENIA
DISPATCH 343
Fig. 1. Links between various cortical and subcortical areas and the parahippocampal gyrus. The projections shown are those
from the same hemisphere. Similar, but often separate projections, arise from subdivisions of one region (the amygdala, for example).
A, amygdala; AA, anterior amygdala; C, caudate; CG, central grey; CL, claustrum; DG, dentate gyrus; GP, globus pallidus; H,
hippocampus; HY, hypothalamus; P, putamen; PG, parahippocampal gyrus; PP, perforant path; S, septum; SI, substantia inominata;
T, thalamus; VT, ventral tegmentum; 6-46, Brodman areas.
One is that the structural changes should be present in
the fetus, and must necessarily precede the onset of obvi-
ous clinical symptoms. Indeed, more subtle alterations in
function or behaviour might be found in infancy, child-
hood and early adulthood, if they were looked for. In
addition, the structural changes might be expected not to
alter or progress during the course of the adult illness.
Although these predictions can be simply stated, given
the nature of the disease, testing them requires a huge
effort. Recent studies have, nevertheless, attempted to
address and test these predictions.
Two such recent studies [8,9] have used prospectively
gathered data, generated by projects (the National Survey
of Health and Development, and the National Child
Development Survey) aimed at investigating and examin-
ing the factors surrounding child birth and development,
to track people who subsequently developed schizo-
phrenia, and to compare their records of development with
those of their peers who remained healthy. The studies
appear to have led to similar findings. Patients destined to
develop schizophrenia showed significant deficits compared
to their peers on a range of behavioural measures.
Importantly, these deficits could be detected from the age
of 4, when the children who later developed schizo-
phrenia showed a greater tendency than other children to
prefer solitary play. Although the deficits were more
marked at early ages, in males at least the deficits -
reduced educational achievement, more anxiety, poor
speech development and poor motor control - were
also seen at the ages of 7, 11 and 15. It should be empha-
sized that these changes are subtle, in that, although the
children's teachers and parents noted differences, there
were no obvious neurological impairments or gross
developmental disorders requiring medical intervention.
The confluence of data contained within these two care-
ful studies is remarkable, and strongly supports the view
that schizophrenia is a developmental disorder. In addi-
tion, the prediction that brain structural abnormalities
associated with schizophrenia should not change during
the course of the illness is borne out by recent studies in
which the brains of schizophrenia patients have been
imaged over periods of years [10].
A remarkable change has thus taken place in our under-
standing of the biology of one of the greatest medical
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Fig. 2. The relative importance of
different factors in the aetiology of
schizophrenia.
problems facing western society - schizophrenia. The
painstaking documentation of the epidemiology, pathol-
ogy and clinical course of the disease reveals a profile
matching that expected of a disorder of brain develop-
ment. Schizophrenia appears to be a familial disorder of
brain development, in which the genetic regulation of
temporal lobe development goes astray (Fig. 2). This has
consequences for the unfolding developmental pro-
gramme of other brain regions and leads, like ripples in a
pond, to diffuse effects on other anatomically linked but
distant brain regions.
Recent advances in our understanding of normal brain
development might provide us with a framework for
understanding other puzzling features of the disease,
such as why the temporal lobe is preferentially affected,
why the left hemisphere tends to be more affected than
the right, and how the deficits caused by aberrant devel-
opment are change from subtle behavioural, social and
cognitive symptoms, which are noticed but tolerated in
childhood, to the full blown delusions, hallucinations
.and thought disorder that overwhelm the adult. These
advances are giving us a clearer view of the molecular
mechanisms of brain development that probably under-
lie the pathogenesis of schizophrenia. Creative fusion
between neuroscience, developmental biology, genetics,
embryology, anatomy and psychiatry is essential if we
are to undo the Gordian Knot of schizophrenia and
dramatically improve therapy.
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